HC Wainwright Reiterates "Buy" Rating for Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report)'s stock had its "buy" rating reiterated by stock analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $10.00 price target on the biopharmaceutical company's stock.

SGMO has been the subject of a number of other reports. Wall Street Zen cut shares of Sangamo Therapeutics from a "hold" rating to a "sell" rating in a report on Friday, May 30th. Royal Bank Of Canada restated a "sector perform" rating and issued a $2.00 price objective on shares of Sangamo Therapeutics in a research note on Tuesday, March 18th. Finally, Barclays reduced their price target on shares of Sangamo Therapeutics from $9.00 to $5.00 and set an "overweight" rating for the company in a report on Wednesday, May 14th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $4.50.

Sangamo Therapeutics Trading Up 18.9%

NASDAQ SGMO traded up $0.08 during trading on Tuesday, reaching $0.51. 23,816,092 shares of the company's stock were exchanged, compared to its average volume of 9,023,249. Sangamo Therapeutics has a fifty-two week low of $0.30 and a fifty-two week high of $3.18. The company's fifty day simple moving average is $0.58 and its 200-day simple moving average is $1.00. The firm has a market capitalization of $119.80 million, a PE ratio of -1.32 and a beta of 1.19.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.03). Sangamo Therapeutics had a negative net margin of 124.61% and a negative return on equity of 345.98%. The company had revenue of $6.44 million for the quarter, compared to analysts' expectations of $7.90 million. Equities analysts forecast that Sangamo Therapeutics will post -0.46 EPS for the current fiscal year.

Hedge Funds Weigh In On Sangamo Therapeutics

A number of hedge funds have recently modified their holdings of SGMO. Wealth Management Associates Inc. raised its stake in shares of Sangamo Therapeutics by 213.7% in the first quarter. Wealth Management Associates Inc. now owns 228,400 shares of the biopharmaceutical company's stock valued at $150,000 after acquiring an additional 155,600 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its holdings in shares of Sangamo Therapeutics by 74.8% during the first quarter. Jacobs Levy Equity Management Inc. now owns 1,297,785 shares of the biopharmaceutical company's stock worth $851,000 after purchasing an additional 555,323 shares during the last quarter. Caption Management LLC acquired a new stake in shares of Sangamo Therapeutics in the first quarter valued at $37,000. OMERS ADMINISTRATION Corp raised its holdings in shares of Sangamo Therapeutics by 93.7% in the first quarter. OMERS ADMINISTRATION Corp now owns 207,800 shares of the biopharmaceutical company's stock valued at $136,000 after buying an additional 100,500 shares during the last quarter. Finally, Invesco Ltd. lifted its position in Sangamo Therapeutics by 82.8% during the 1st quarter. Invesco Ltd. now owns 483,894 shares of the biopharmaceutical company's stock worth $317,000 after buying an additional 219,253 shares in the last quarter. 56.93% of the stock is owned by institutional investors and hedge funds.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.